Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia by Pezzolo, A et al.
Oncotarget10368www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 21
Failure of anti tumor-derived endothelial cell immunotherapy 
depends on augmentation of tumor hypoxia
Annalisa Pezzolo1, Danilo Marimpietri1, Lizzia Raffaghello1, Claudia Cocco1, Angela 
Pistorio2, Claudio Gambini3, Michele Cilli4, Alberto Horenstein5, Fabio Malavasi5 
and Vito Pistoia1
1 Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy
2 Unità di Epidemiologia e Biostatistica Istituto Giannina Gaslini, Genova, Italy
3 Laboratorio di Anatomia Patologica Istituto Giannina Gaslini, Genova, Italy 
4 Animal Research Facility, IRCCS-AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova 
5 Laboratorio di Immunogenetica, Università di Torino, Italy
Correspondence to: Annalisa Pezzolo, email: annalisapezzolo@ospedale-gaslini.ge.it
Keywords: epithelial-mesenchymal transition, hypoxia, neuroblastoma, tumor-derived endothelial cells, vascular mimicry
Received: March 14, 2014 Accepted: May 26, 2014 Published: May 26, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
We have previously demonstrated that Tenascin-C (TNC)+ human neuroblastoma 
(NB) cells transdifferentiate into tumor-derived endothelial cells (TDEC), which 
have been detected both in primary tumors and in tumors formed by human NB 
cell lines in immunodeficient mice. TDEC are genetically unstable and may favor 
tumor progression, suggesting that their elimination could reduce tumor growth 
and dissemination. So far, TDEC have never been targeted by antibody-mediated 
immunotherapy in any of the tumor models investigated. 
To address this issue, immunodeficient mice carrying orthotopic NB formed by 
the HTLA-230 human cell line were treated with TDEC-targeting cytotoxic human 
(h)CD31, that spares host-derived endothelial cells, or isotype-matched mAbs. 
hCD31 mAb treatment did not affect survival of NB-bearing mice, but increased 
significantly hypoxia in tumor microenvironment, where apoptotic and proliferating 
TDEC coexisted, indicating the occurrence of vascular remodeling.
Tumor cells from hCD31 mAb treated mice showed i) up-regulation of epithelial-
mesenchymal transition (EMT)-related and vascular mimicry (VM)-related gene 
expression, ii) expression of endothelial (i.e. CD31 and VE-cadherin) and EMT-
associated (i.e. Twist-1, N-cadherin and TNC) immunophenotypic markers, and iii) 
up-regulation of high mobility group box-1 (HMGB-1) expression. In vitro experiments 
with two NB cell lines showed that hypoxia was the common driver of all the above 
phenomena and that human recombinant HMGB-1 amplified EMT and TDEC trans-
differentiation.
In conclusion, TDEC targeting with hCD31 mAb increases tumor hypoxia, setting 
the stage for the occurrence of EMT and of new waves of TDEC trans-differentiation. 
These adaptive responses to the changes induced by immunotherapy in the tumor 
microenvironment allow tumor cells to escape from the effects of hCD31 mAb.
INTRODUCTION
Tumor growth is critically dependent on adequate 
blood supply provided by newly formed endothelial 
micro-vessels (EM) [1-3]. Tumor cells themselves may 
contribute to vascularization by assembling into vascular-
like channels according to a process referred to as vascular 
mimicry (VM). [4].
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Neuroblastoma (NB) is an embryonal tumor arising 
from sympathetic neuronal progenitor cells that accounts 
for 15% of all pediatric cancer deaths [5-7]. We previously 
identified in primary NB tumors, as well as in orthotopic 
tumors formed in immunodeficient mice by different 
human NB cell lines, tumor-derived endothelial cells 
(TDEC) harboring MYCN amplification as the NB cells 
from which they originated [8-10]. More recently, we have 
identified perivascular NB progenitor cells expressing 
Tenascin C (TNC) on the cell surface, that displayed a high 
degree of plasticity and served as TDEC progenitors [10]. 
TDEC are genetically unstable and contribute to chemo-
resistance and tumor progression [11].
A hypoxic microenvironment is of pivotal 
importance for tumor growth. Hypoxia inducible factors 
regulate hypoxia responsive genes and play critical roles 
in tumor invasion, metastasis, and chemoresistance [12].
Epithelial-mesenchymal transition (EMT) is an 
embryonic process leading to the loss of cell-cell contact, 
repression of E-cadherin expression and increased cell 
motility. EMT can also occur in cancer cells, in which it 
is associated with resistance to chemotherapeutic drugs 
and radiation [13], and increased stemness, motility, 
invasiveness, as well as angiogenic and metastatic ability 
[13, 14]. An hypoxic tumor microenvironment is one of 
the major EMT inducers [15, 16].
We have hypothesized that selective elimination of 
TDEC might reduce tumor growth. To address this issue, 
we have here selectively targeted TDEC in an orthotopic 
mouse model of human NB using a cytotoxic hCD31 mAb 
that does not react with mouse endothelial cells (mEC). 
Our findings demonstrate that hCD31 mAb-induced 
enhancement of tumor hypoxia activates i) EMT and ii) 
trans-differentiation of malignant cells into TDEC, both 
of which in turn account for the failure of such therapeutic 
approach.
RESULTS
Tumor-derived endothelial cells (TDEC) 
contribute to tumor vascularization in an 
orthotopic mouse model of human NB
Immunodeficient mice were inoculated in the 
adrenal gland with the human NB cell line HTLA-230 
that, according to previous studies from our group [8-10], 
best mimics human NB growth and progression. Mice 
were treated with the hCD31 cytotoxic Moon-1 mAb 
[17] or isotype-matched control mAb. Supplementary 
Fig. 1 shows that the hCD31 mAb Moon-1 stained human 
TDEC, but not mEC.
All experiments were performed with tumors 
harvested eighteen days after NB cell inoculation. Such 
time point was selected on the ground of our previous 
studies showing that tumor-derived and mouse-derived 
EM, although displaying different kinetics of formation, 
are present in similar proportions after approximately two 
weeks from HTLA-230 NB cell inoculation [10].
Tumors from mice treated with hCD31 mAb (n=7) 
were significantly smaller than control tumors (n=7) (p= 
0.047) (Fig. 1A), but treatment with hCD31 mAb did not 
prolong survival of tumor bearing (n=14) vs control (n=14) 
mice (Fig. 1B). Human EM density, assessed by hCD31 
staining, decreased significantly (p= 0.011) in orthotopic 
tumors from hCD31 mAb treated (n=7) vs control (n=7) 
mice (Fig. 2A). Accordingly, apoptotic hCD31+ EM 
(defined as EM containing at least three TUNEL+ TDEC) 
increased significantly (p= 0.036) in the former (n=5) vs 
the latter (n=5) tumors (Fig. 2B and 2C, panel 1). Focal 
micro-vascular destruction and hemorrhagic areas were 
detected in tumors from hCD31 mAb treated mice (Fig. 
2C, panel 2).
Double staining of NB tissue sections with hCD31 
mAb and anti-Ki-67 mAb, that identifies proliferating 
cells, showed that hCD31+, Ki-67+ EM (defined as 
EM containing at least three Ki-67+ TDEC) increased 
significantly (p= 0.006) in tumors from hCD31 mAb 
treated vs control mice (Fig. 2B and 2C, panel 3), 
indicating the occurrence of human EM remodeling.
Mouse EM integrity was unaffected by hCD31 mAb 
treatment (Fig. 2C, panel 4) and mouse EM density was 
increased in tumors from hCD31 mAb treated vs control 
mice (p< 0.0001) (Fig. 2A).
hCD31 mAb immunotherapy increases tumor 
hypoxia
TDEC depletion induced by hCD31 mAb treatment 
may reduce blood supply and increase tumor hypoxia. 
Hypoxia inducible factor-2α (HIF2α) is up-regulated in 
NB cells during hypoxic conditions and represents the 
most reliable hypoxic marker in NB [19]. In addition, 
HIF2α has been associated with developing endothelium 
[20].We stained by immunofluorescence orthotopic NB 
tissue sections from hCD31 treated (n=7) or control 
(n=7) mice with anti-HIF2α mAb [19]. The proportion of 
HIF2α+ cells was significantly higher in the former than in 
the latter tumors (61.9±3.22% vs 20.7± 6.18%, p= 0.0001) 
(Fig. 2C, panels 5 and 6).
In essence, TDEC contributed to NB vascularization 
since their targeting with hCD31 mAb reduced tumor 
size, decreased the number of human EM and increased 
hypoxia in tumor microenvironment.
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Figure 1: Effect of hCD31 mAb treatment on tumor growth and survival in orthotopic NB bearing mice . A) Tumors 
from mice treated with hCD31 mAb (n = 21) and sacrificed after 18 days from NB cell inoculation were significantly smaller than control 
tumors (n = 21) (CD31 vs control p= 0.047). B) Treatment with hCD31 mAb had no effect on survival of tumor bearing mice which was 
superimposable to that of control mice.
Figure 2: Endothelial micro-vessels in NB tumors from hCD31 mAb treated mice. A) hCD31+ (red) and mCD34+ (blue) 
EM per field in tumors from hCD31 mAb vs isotype treated mice harvested after 18 days from tumor cell inoculation. Small circles 
represent median values, boxes represent 25%-75% and bars represent minimum and maximum values. B) Apoptotic (TUNEL+) and 
proliferating (Ki-67+) human EM increased significantly (p=0.036 and p=0.006, respectively) in tumors from hCD31 mAb treated vs 
control mice. Columns represent mean values; bars represent 95% Confidence Intervals. C) Immunofluorescence analysis of tumors from 
hCD31 mAb treated mice: 1) double staining for hCD31 mAb (red) and TUNEL (green) detects human apoptotic EM, 2) focal micro-
vascular destruction (white arrows) of hCD31+ EM (green); 3) double staining for hCD31 mAb (green) and Ki-67 (red) detects human 
proliferating EM (white arrows); 4) viable mCD34+ EM (green); 5, 6) NB tissue sections from control and hCD31 mAb treated mice 
stained with anti-hypoxia inducible factor-2α (HIF2α) mAb. NB tumors harvested after 18 days were studied (n = 7 tumors/group). Images 
in C illustrate representative data from one of at least three independent experiments.
Oncotarget10371www.impactjournals.com/oncotarget
hCD31 mAb immunotherapy up-regulates 
expression of human pro-angiogenic genes in NB 
cells
We next investigated the angiogenic phenotype of 
tumors from hCD31 mAb treated (n=4) vs control (n=4) 
mice using PCR arrays specific for selected human or 
mouse angiogenic transcripts. hCD31 mAb treatment 
caused up-regulation (range 1,000-160,000 fold) of the 
expression of different human pro-angiogenic genes 
including CCL11, CXCL3, CXCL5, cadherin 5 (CDH5), 
also known as vascular endothelial (VE)-cadherin, 
collagen type IVα3 (COL4A3), vascular endothelial 
growth factor (VEGF), platelet derived growth factor-A 
(PDGFA), fibroblast growth factor-1 (FGF1), TNF and 
IL-6 (Fig. 3A, black bars). High expression of these pro-
angiogenic genes, the majority of which are not species-
specific, likely accounts for the increased numbers of 
mouse-derived EM in NB tumors from h-CD31 mAb 
treated mice.
Two distinctive “signatures” related to VM [21] 
and epithelial mesenchymal transition (EMT) [22-24], 
respectively, were identified. In particular, VM-related 
transcripts included VE-cadherin (CDH5), collagen IV 
(COL4A), endothelial differentiation receptor (EDG1), 
IL-6, TNF-induced protein 2 (TNFAIP2), the matrix 
metalloproteinase MMP2, jagged-1 (JAG1), i.e. the ligand 
for the receptor Notch-1, and thrombospondin-1 (THBS1) 
Figure 3: Human and mouse angiogenic gene expression in orthotopic NB tumors from anti-hCD31 mAb treated mice. 
NB tumors from hCD31 mAb treated mice were harvested after 18 days. A) Human angiogenesis PCR array analysis of one representative 
NB tumor (out of four) from hCD31 mAb treated vs control mice. Pro-angiogenic genes, black bars; anti-angiogenic genes, grey bars. B) 
Mouse angiogenesis PCR array analysis of one representative NB tumor (out of four) from anti-hCD31mAb treated vs control mice. Pro-
angiogenic genes, black bars; anti-angiogenic genes, grey bars. Assays for each experiment were performed in triplicate.
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[21]. EMT-related transcripts included epidermal growth 
factor (EGF), hepatocyte growth factor (HGF), insulin 
growth factor-1 (IGF-1), TNF, CXCL5, IL-6, FGF-1, 
PDGFA and MMP2 [22-25].
Expression of some human anti-angiogenic genes 
including interferon (IFN)A1, IFNB1, CXCL9, CXCL10 
and Leukocyte cell derived chemotaxin-1 (LECT1) was 
also increased following hCD31 treatment (Fig. 3A, grey 
bars), perhaps in response to massive up-regulation of 
pro-angiogenic genes. In contrast, expression of mouse 
angiogenesis related genes was unaffected or dampened 
by hCD31 treatment (Fig. 3B).
We next asked whether human TDEC targeting 
altered the number and/or proliferative status of TNC+/
Oct-4+ NB vascular progenitor cells [10], identified by 
TNC surface staining, and MYCN FISH. TNC+ NB cells 
carrying MYCN amplification, that showed a perivascular 
distribution [10], increased significantly in tumors from 
hCD31 treated (n=5) vs control (n=5) mice (p= 0.0012) 
(Fig. 4). Furthermore, the fraction of proliferating (Ki-67+) 
TNC+ cells was 8% (11/141) in hCD31 treated and 3% 
(5/154) in control mice (p< 0.0001; 95% Binomial Exact 
Confidence Interval).
Thus, TDEC remodeling triggered by hCD31 mAb-
driven depletion of TDEC caused an increase of cycling 
TNC+ vascular progenitor NB cells, likely setting the stage 
for TDEC replenishment.
NB vascular progenitor cells express the neural 
Tenascin C isoform A1, A2, A4, B
TNC is encoded by a single gene and its expression 
is regulated by a single promoter [26]. Structurally and 
Figure 4: TNC+/Oct-4+ NB cell enumeration in tumors 
from hCD31 mAb treated mice. NB tumors from hCD31 
mAb treated (n = 5) or control (n = 5) mice were harvested after 
18 days. Numbers of TNC+/Oct-4+ cells, that represent TDEC 
progenitors, per field were assessed by immunofluorescence. 
Small circles represent median values, boxes represent 25%-
75% and bars represent minimum and maximum values.
Figure 5: Expression of the large TNC isoform containing the A1, A2, A4, and B FnIII domains. Upper panel shows 
schematic representation of the TNC protein. The domain structure of TNC comprising N-terminal assembly domain is followed by 
epidermal growth factor (EGF)-like repeats, the fibronectin type III (fnIII)-like repeats and the fibrinogen-like domain. The fnIII region 
consists of eight conserved repeats, designated 1 to 8, and up to nine alternatively spliced fnIII repeats designated as letters A to D. Lower 
panels show the immunofluorescence images after double staining of orthotopic tumor tissue sections formed by HTLA-230 cells in 
immunodeficient mice (n=5) with BC-2 (A1 and A4 specific), α/A2 (A2 specific) and BC-3 (B specific) mAbs (all in red), and hCD31 
mAb (green). Representative images of one out of three experiments performed are shown.
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functionally different human TNC isoforms are generated 
by alternative splicing of the TNC transcript [26]. TNC 
is a multi-modular protein with a cysteine-rich assembly 
domain, epidermal growth factor (EGF)-like domains, 
several fibronectin type III (FnIII) domains, and a 
fibrinogen-like domain [25]. Up to six additional domains 
can be inserted between the fifth and sixth domain by 
alternative splicing domains (A1 to A4, B, C and D) [18, 
27]. To identify what isoform(s) of TNC was expressed 
by NB progenitor cells, we used a series of murine mAbs 
specific for different alternatively spliced domains of 
this molecule [18]. Only the TNC isoform containing the 
alternatively spliced FnIII domains A1, A2, A4, and B was 
consistently detected in TNC+ NB vascular progenitor 
cells present in orthotopic NB tumors (n=4) (Fig. 5). This 
large TNC isoform is selectively expressed in neural stem/
progenitor cells [28].
hCD31 mAb immunotherapy induces epithelial-
mesenchymal transition in orthotopic NB tumors
Detection of an EMT “signature” in NB cells from 
hCD31 mAb treated mice prompted experiments in 
which tumor tissue sections were stained with mAbs to 
Twist-1, the master regulator of EMT [29], N-cadherin and 
E-cadherin.
Most tumor cells from control mice (n=7) showed 
cytoplasmic expression of Twist-1 (83±5%), consistent 
with its transcriptional inactive state [29] (Fig. 6A, panel 
1). The same cells expressed E-cadherin (98±2%) (Fig. 
6A, panel 3) but not N-cadherin (Fig. 6A, panel 5).
In contrast, tumors from hCD31 mAb treated mice 
Figure 6: Expression of EMT proteins in orthotopic NB tumors from hCD31 mAb treated mice and in human NB cell 
lines incubated in vitro under normoxia or hypoxia. . A) Immunofluorescent staining of paraffin sections of orthotopic NB tumors 
from mice treated with hCD31 (n= 7) or control mice (n=7). Staining for Twist-1 (1, 2), E-cadherin (3, 4), N-cadherin (5, 6), HMGB-1 (7, 
8). The Figure shows one representative experiment out of the four performed.. B) HTLA-230 cells were incubated in hypoxic or normoxic 
environment for 48h. Expression of EMT-related and endothelial markers, as well as of HMGB-1, was detected by immunofluorescent 
staining. Staining for Twist-1 (1, 2), E-cadherin (3, 4), N-cadherin (5, 6), hCD31 (7, 8), VE-Cadherin (9, 10), TNC (11, 12) and HMGB-
1 (13, 14). Nuclei are stained with DAPI (blue). Original magnification 40x. One representative experiment out of the four performed is 
shown.
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(n=7) showed in most of the cells nuclear expression of 
Twist-1 (79±7%), indicative of ongoing transcriptional 
activity [29] (Fig. 6A, panel 2). In addition, NB cells 
displayed expression of N-cadherin (98±3%) (Fig. 6A, 
panel 6) but not E-cadherin (Fig. 6A, panel 4). These 
results confirmed the onset of EMT [30] in tumors from 
hCD31 mAb treated mice.
Hypoxia may up-regulate the expression of high-
mobility group box protein-1 (HMGB-1) [31], that acts 
as extracellular signaling molecule during inflammation, 
angiogenesis, cell differentiation, cell migration, and 
tumor metastasis [32-35]. Indeed, HMGB-1+ cells were 
significantly increased in tumors from hCD31 mAb treated 
(n=7) vs control (n=7) mice (77.3±8.2% vs 11.0±2.7%, p= 
0.0004). HMGB-1 was always detected in the cytoplasm 
of NB cells (Fig. 6A, panels 7 and 8), suggesting a role of 
this molecule in the stimulation of cell motility [32-35].
In vitro culture of HTLA-230 NB cells under 
hypoxic conditions induces expression of epithelial 
mesenchymal transition-related and endothelial 
cell-related markers, as well as of HMGB-1
In order to investigate the in vitro conditions 
allowing expression of EMT-related and endothelial 
markers in NB cells, HTLA-230 cells were incubated in 
hypoxia (1% O
2
) or normoxia for 24-72 h. In four different 
experiments, cytoplasmic Twist-1 was detected in 80±13% 
cells under normoxia only (control) (Fig. 6B, panel 1), 
whereas nuclear Twist-1 was detected in 76±5% HTLA-
230 cells under hypoxia only (Fig. 6B, panel 2). Hypoxia 
induced down-regulation of E-cadherin (<1%), while 
strong basal expression of the latter marker (mean± SD 
82±7%) was detected in normoxic cells (Fig. 6B, panels 
Figure 7: Incubation of NB cell lines in vitro with HMGB-1 induces expression of EMT-related and endothelial 
markers. A) Immunofluorescence staining of cytospins of the HTLA-230 cell line cultured for 48 h in the absence or presence of human 
recombinant HMGB-1 protein (10μg/ml). Cytospins were stained for N-cadherin (1, 2), E-cadherin (3, 4), VE-cadherin (5, 6), CD31 (7, 8), 
PSMA (9, 10) and Oct-4 (11, 12). Nuclei are stained with DAPI (blue). Original magnification 40x. One representative experiment out of 
the four performed is shown..B) Expression of TNC, VE-cadherin and CD31 were evaluated by flow cytometry in HTLA-230 and IMR-32 
cell lines cultured in the presence or absence of HMGB-1 as above. Results are expressed as MRFI and represent means ±SD from three 
independent experiments.
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3 and 4, respectively). Conversely, hypoxia induced de 
novo expression of N-cadherin (mean ±SD 85±10%) that 
was detected in less than 1% normoxic cells (Fig. 6B, 
panels 5 and 6). Under hypoxia, HTLA-230 cells acquired 
expression of the endothelial-specific markers CD31 
(mean ±SD 35±9% ) (Fig. 6B, panels 7 and 8) and VE-
cadherin (mean ±SD 72±6%) (Fig. 6B, panels 9 and 10), 
that were undetectable in normoxic cells. Furthermore, 
TNC+ cells, that serve as TDEC progenitors [10], were 
significantly increased in hypoxic compared to normoxic 
NB cells (means ±SD: 20.0±4.3% vs 10.0±2.7%, p= 
0.006) (Fig. 6B, panels 11 and 12). Finally, most HTLA-
230 cells cultured in hypoxia acquired the expression of 
HMGB-1, that was virtually undetectable in normoxic 
cells.
These data establish definitively that hypoxia 
induces expression of EMT-related and endothelial 
markers in NB cells.
HMGB-1 mimics hypoxia in vitro
Since HMGB-1 induces EMT in lung [32] and renal 
[34] fibrosis, we finally investigated whether HMGB-
1 behaved similarly in our human NB models under 
normoxic conditions. In four different experiments, 
HTLA-230 cells were cultured with HMGB-1 for 24-
72 h. Fig. 7A shows that HTLA-230 cells cultured with 
HMGB-1 acquired the expression of N-cadherin and lost 
that of E-cadherin, indicative of an ongoing EMT. The 
same cells expressed de novo VE-cadherin (mean ±SD 
87±4.3%), CD31 (mean ±SD 30±2.5%), and PSMA [10] 
(mean ±SD 75±1%), witnessing the occurrence of trans-
endothelial differentiation of NB cells. Accordingly, 
TDEC progenitors expressing Oct-4 both in the nucleus 
and the cytoplasm were doubled in HTLA-230 cells 
incubated with HMGB-1 compared to control (means 
±SD: 18.0±3% vs 9.0±3.2%, p= 0.008) (Fig. 7A).
Figure 8: A model for hypoxia-driven EMT and trans-endothelial differentiation of NB cells. TDEC targeting with cytotoxic 
hCD31 mAb enhances tumor hypoxia, which in turn induces EMT and endothelial trans-differentiation of tumor cells. Both of the latter 
phenomena increase the proportion of TNC+/Oct-4+ NB cells, that differentiate into TDEC responsible for the vascular remodeling observed 
in tumors from hCD31 treated mice. In addition, hCD31 mAb-driven hypoxia promotes in NB cells expression of HGMB-1 that induces by 
itself EMT and endothelial trans-differentiation of tumor cells, thus mimicking the effects of hypoxia and serving as an amplification loop. 
All of these mechanisms in combination account for the refractoriness of NB tumors to TDEC targeting with hCD31 mAb.
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When HTLA-230 and IMR-32 NB cell lines were 
treated with HMGB-1 and analyzed by flow cytometry 
(n=3 experiments), both cell lines variably up-regulated 
the expression of TNC, VE-cadherin and CD31, thus 
confirming that HMGB-1 induced the acquisition of EMT-
related (TNC) and endothelial (VE-cadherin and CD31) 
markers (Fig. 7B).
DISCUSSION
Primary NB tumors may contain a variable number 
(range 20-78%) of TDEC carrying the same genomic 
alteration as tumor cells [10]. TNC+ perivascular NB 
cells serving as TDEC progenitors have been identified in 
primary NB samples, metastatic bone marrow aspirates, 
NB cell lines, and orthotopic tumors formed by these cell 
lines in immunodeficient mice [8-10].
Studies aimed at targeting TDEC, that are 
genetically unstable and contribute to tumor progression 
[11], have shown that thalidomide, sirolimus, curcumin, 
isoxanthohumol or resveratrol inhibited TDEC formation 
in various pre-clinical models [36]. Differentiation of 
CD133+ glioblastoma stem cells into TDEC [37-39] was 
unaffected by anti-VEGF mAb, but blocked by γ-secretase 
inhibition or Notch-1 silencing [39]. 
Here we have targeted for the first time human 
TDEC in vivo with the cytotoxic hCD31 mAb Moon-1, 
taking advantage of its high specificity witnessed by the 
lack of any reactivity with host-derived EC. Significant 
decrease of TDEC due to apoptosis and reduction of 
tumor size unambiguously proved that TDEC contributed 
to NB growth. However, tumors harvested at the end 
of immunotherapy cycles displayed active vascular 
remodeling, as shown by detection of proliferating TDEC. 
In this respect, treatment with VEGF inhibitors or VEGF 
gene inactivation in preclinical mouse models of cancer 
were previously found to increase tumor invasiveness and 
metastasis, as well as EC proliferation, that could play 
a role in a putative rebound dampening anti-angiogenic 
treatment efficacy [40-42].
Hypoxia-inducible factor renders cells capable 
of surviving in hypoxia and stimulates endothelial cell 
growth [43]. On one hand, hypoxia inhibits the mTOR 
pathway, mTOR-dependent translation of HIF-1 and 
prevents senescent phenotype [44]. On the other hand, 
hypoxia strongly posttranslationally induces HIF-1, 
which increases secretion of mitogens and cytokines, 
markers of cellular senescence and promotes it [43]. We 
reasoned that hypoxia could drive vascular remodeling in 
NB tumors from mice treated with hCD31 mAb [45, 46]. 
Indeed, a highly significant increase of HIF-2α expression 
was detected in tumors from hCD31 mAb treated mice, 
indicating that TDEC targeting resulted into generation 
of a strongly hypoxic tumor microenvironment. Hypoxia 
was previously shown to induce expression of VM-related 
genes [21]. Indeed, up-regulation of the expression of 
VM-related and other pro-angiogenic genes was detected 
by PCR array in tumors from hCD31 mAb treated mice. 
Angiogenic factors, which are produced by tumor cells 
in response to hypoxia, reduce the pro-apoptotic potency 
of chemotherapy on endothelial cell [47]. By activating 
hypoxic response in tumor cells, antiangiogenic therapy 
may promote metastasis and invasion [47]. 
Hypoxia is also an inducer of EMT, characterized 
by loss of cell junction and gain of migratory behavior 
[30, 33]. Twist-1 is a basic helix-loop-helix transcription-
factor that promotes EMT [48-50] through i) repression 
of E-cadherin [48], leading to disassembly of adherens 
junctions and increased migratory potential [50], and ii) 
up-regulation of mesenchymal markers, as N-cadherin and 
TNC [49]. In our experiments, tumors from hCD31 mAb 
treated mice showed nuclear translocation of Twist-1, 
lost E-cadherin expression and acquired N-cadherin 
expression, indicating the occurrence of hCD31 mAb-
initiated EMT. These findings were corroborated by the 
results of PCR array analysis of tumors from hCD31 mAb 
vs isotype treated mice showing the presence of an EMT-
related “signature” in the former tumors.
Damage associated molecular patterns (DAMPs) 
are released by dying cells [51]. The main DAMP is 
HMGB-1 [52, 53], that promotes angiogenesis, evasion 
of programmed cell death, self-sufficiency in growth 
signals, insensitivity to inhibitors of growth, autophagy, 
and tissue invasion and metastasis [52-54]. Tumor 
angiogenesis is enforced by autocrine regulation of 
HMGB-1 in EC through increased expression of key pro-
angiogenic genes as PDGF-A, FGF and MMP-2 [55], 
that we found to be strongly up-regulated in tumors from 
hCD31 mAb treated mice. We asked whether the latter 
tumors expressed HMGB-1. Indeed, most tumor cells 
from hCD31 mAb treated mice expressed HMGB-1, 
that was barely detectable in control tumors, suggesting 
that hypoxia augmented by hCD31 mAb treatment up-
regulated HMGB-1 [52-54].
The results of in vivo experiments were confirmed 
by in vitro studies with NB cell lines incubated in hypoxia. 
These cells i) acquired expression of N-cadherin and 
nuclear Twist-1 and lost that of E-cadherin, ii) expressed 
de novo the EC-related markers CD31 and VE-cadherin, 
as well as HMGB-1, and iii) up-regulated the expression 
of TNC that, beside representing an EMT marker [56], 
identifies NB TDEC progenitors [10]. The latter finding 
is consistent with the significant increase of TNC+/Oct-
4+ cycling TDEC progenitors observed in tumors from 
hCD31 mAb treated mice.
HMGB-1 can induce EMT in human kidney tubular 
epithelial cells [34] and mouse alveolar epithelial cells 
[32]. We found that HMGB-1 induced expression of EMT 
and EC markers in NB cells cultured in normoxia, thus 
mimicking the effects of hypoxia. HMGB-1 conceivably 
bound to NB cells through Toll-like receptor 4 (TLR-4), 
and/or RAGE [57], that have been shown in previous 
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studies to be expressed by these cells [58]. It is tempting 
to speculate that HMGB-1 synergizes with hypoxia sub-
serving the same or similar functions in less hypoxic or 
normoxic areas of the tumor mass.
Taken together, our results indicate that hypoxia-
driven enhancement of VM and onset of EMT represent 
adaptive mechanisms to the perturbation of tumor 
microenvironment caused by hCD31 mAb treatment. 
Notably, in this respect, nuclear translocation of Twist-1 
[29] initiated VM in hepatocellular [29, 50] and colorectal 
[59] carcinomas, showing that EMT and VM are linked.
Additional mechanisms beside hypoxia may 
contribute to the onset of EMT in tumors from hCD31 
mAb treated mice. IL-6, whose expression was up-
regulated in the latter tumors, is a well known inducer of 
EMT and mediates trastuzumab resistance in breast cancer 
[60]. Anaphylotoxins as C3a and C5a, generated in our 
study by hCD31 mAb-mediated complement activation, 
regulate EMT in non-malignant disease models [61, 62].
In conclusion, we propose the following model (Fig. 
8). TDEC targeting with cytotoxic hCD31 mAb enhances 
tumor hypoxia, which in turn induces EMT and promotes 
endothelial trans-differentiation of tumor cells. Both of 
the latter phenomena increase the proportion of TNC+/
Oct-4+ NB cells, that differentiate into TDEC responsible 
for the vascular remodeling observed in tumors from 
hCD31 mAb treated mice. In addition, hCD31 mAb-
driven hypoxia promotes in NB cells expression of 
HGMB-1 that induces by itself EMT and endothelial 
trans-differentiation of tumor cells, thus serving as an 
amplification loop of hypoxia (Fig. 8). Altogether these 
mechanisms account for the refractoriness of NB tumors 
to TDEC targeting with hCD31 mAb. A potential strategy 
to exploit hypoxia for therapeutic purposes might be to 
combine an antiangiogenic treatment with inactive pro-
drugs that are activated by hypoxia [47].
METHODS
Orthotopic mouse model of human neuroblastoma
Seven/eight week old female athymic nude (nude/
nude) mice from Harlan Laboratories (Harlan Italy, S. 
Pietro al Natisone, Italy) were housed in sterile enclosures 
under specific pathogen-free conditions. Mice were 
subjected to laparotomy, and injected with HTLA-230 
cells (1.5×106 cells in 20 μl of saline solution) in the left 
adrenal gland [10]. Mice were anesthetized with ketamine 
(Imalgene 1000, Merial Italia SpA., Milan, Italy) and 
sacrificed by cervical dislocation. All procedures involving 
animals were performed in the respect of the National and 
International current regulations (D.lvo 27/01/1992, n° 
116, European Economic Community Council Directive 
86/609, OJL 358, Dec. 1, 1987) and were reviewed and 
approved by the licensing and Ethical Committee of the 
IRCCS-AOU San Martino-IST National Cancer Research 
Institute, Genoa, Italy, and by the Italian Ministry of 
Health.
Treatment of neuroblastoma bearing mice with 
hCD31 mAb
Tumor bearing mice were allocated randomly into 
three groups of seven mice each to receive intravenously 
(iv) the hCD31 Moon-1 purified mAb (IgG
2
, 450 μg/
mouse) [17], or isotype-matched IgG
2
 irrelevant mAb 
(450 μg/mouse) for two weeks starting from day 2 after 
tumor cell inoculation. Treatment was administered every 
three days for a total of five injections. This protocol was 
repeated in three different experiments.
Quantification of tumor growth
Mice were sacrificed i) when they showed signs 
of poor health to evaluate survival or ii) the day after 
the conclusion of last cycle of antibody treatment, i.e. 
day 18, in order to measure tumor volume and perform 
histological and immunohistochemical studies. Tumor 
volume was measured with a caliper using the following 
formula: Volume = π/6 x (w1 x w2) (w1= largest tumor 
diameter; w2 smallest tumor diameter). For histological 
analyses tissue sections were stained with hematoxylin 
and eosin.
Immunofluorescence analysis and quantifications 
of micro-vessel density
Indirect immunofluorescence was performed on 
formalin-fixed, paraffin embedded or on cryopreserved 
tissue sections from mice sacrificed, or on cytospins of 
the HTLA-230 cell line as previously described [10]. 
Paraffin sections (2-4 μm thick) were processed by 
standard deparaffinization with xylene and hydrated in 
a descending ethanol series to double-distilled water. 
Antigen retrieval on formalin-fixed tissue section 
was performed using Sodium-Citrate buffer (pH 6.0). 
Indirect immunofluorescence was performed using 
the following mouse monoclonal antibodies (mAbs): 
anti-human(h)CD31 (diluted 1/50; Dako Cytomation, 
Hamburg, Germany), anti-mouse(m)CD34 (1/50; Novus 
Biologicals, Littleton, CO, USA), anti-hOct-4 (1/50, Clone 
3A5; Abcam Inc, Cambridge, USA), anti-hTenascin C 
(1/50; Millipore, Milan, Italy), anti-Ki-67 (1/60; Dako 
Cytomation), anti hE-cadherin (1/25, Clone EP700Y; 
Millipore), anti hN-cadherin (1/25, Clone EPR1792Y; 
Millipore), anti-hTwist-1 (1/50, Sigma-Aldrich, St. Louis, 
MO, USA), anti hHMGB-1 (1/20, Clone 1B11, Abnova, 
Taipei, Taiwan), anti-hVE-cadherin (1:50; Chemicon 
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International, Millipore, Billerica, MA, USA), and anti-
HIF2α (1:100; Novus Biologicals) were used. In addition, 
we used the following mouse mAbs (1/20 dilution) specific 
for the different epitopes of hTNC, generously donated by 
Dr L. Zardi, Syrius Biotech, Genoa, Italy: anti BC-7, anti 
BC-4, anti BC-8, anti BC-6, anti BC-9, anti BC-2, anti-
III8TN, anti-α/A2, anti BC-3, anti-III12TN [18]. Isotype-
matched nonbinding mAbs were used in all antibody-
staining experiments to exclude non specific reactivities. 
Slides were incubated with primary antibodies overnight 
at 4° C. Secondary antibodies were goat anti-mouse IgG 
conjugated to Alexa-488 or goat anti-rabbit IgG Alexa-568 
(1:200; Invitrogen, Germany). After washing, the slides 
were counterstained with 4’,6’-diamidino-2- phenylindole 
(DAPI, Sigma-Aldrich, Milan, Italy) and cover-slipped.
EM density was assessed by anti-hCD31 or anti-
mCD34 staining and examination of twenty to fifty 
microscopic fields (0.5 mm2) per tumor. We have shown 
in a previous study that the anti-hCD31 or anti-mCD34 
mAbs used in this study are rigorously species-specific 
[10]. The most intense vascular areas (hotspots) were 
selected subjectively from each tumor section. EM with a 
clearly defined lumen or well-defined linear vessel shape 
were taken into account for EM counting. 
Detection of apoptotic or proliferating endothelial 
cells
Apoptosis was evaluated using in situ Cell Death 
Detection Kit (Roche Diagnostics, Penzberg, Germany). 
The Terminal Deoxynucleotidyl Transferase-Mediated 
dUTP Nick-End Labeling (TUNEL) reaction was carried 
out by incubating tumor tissues with FITC-dUTP labeled 
nucleotides and terminal deoxynucleotidyl transferase 
(TdT), which catalyzes polymerization of labeled 
nucleotides to free 3’-OH DNA ends. Apoptotic or 
proliferating cells were detected by staining for TUNEL 
or Ki-67, respectively, in combination with hCD31. 
Apoptotic or proliferating EM were operationally defined 
as containing at least three TUNEL+ or Ki-67+ cells, 
respectively.
Fluorescent In Situ Hybridization (FISH)
Interphase FISH was performed on paraffin-
embedded tumor tissue sections as described [10] 
using rhodamine-labeled MYCN-specific DNA probe 
(QBIOgene Inc, Hamburg, Germany) and mouse Cot-
1 DNA probe (Life Technologies Gibco BRL, Paisley, 
Scotland).
PCR-Array profiling
RNA was extracted using TRIZOL® from 
Invitrogen (Carlsbad, CA, USA) and reverse transcribed 
by the ReactionReady™ First Strand cDNA Synthesis 
kit (SuperArray Bioscience Corporation). Human and 
murine angiogenesis RT2 Profiler™ PCR Array and RT2 
Real-Timer™ SyBR Green/ROX PCR was performed 
according to the instructions of the manufacturer on ABI 
Prism™ 7700 Sequence Detector (Applied Biosystems).
Cell culture and human recombinant HMGB-1 
protein treatment of HTLA-230 and IMR-32 cell 
lines
HTLA-230 and IMR-32 cells were maintained 
as previously described [10]. HTLA-230 and IMR-32 
NB cells were cultured on glass slide containing dishes 
(Millipore) with or without human recombinant HMGB-
1 protein (10μg/ml, Sigma-Aldrich) for 72 h. E-cadherin, 
N-cadherin, Twist-1, TNC, CD31 and VE-cadherin 
expression were assessed by immunofluorescence staining.
Flow cytometry
TNC, CD31 and VE-cadherin expression was 
investigated on HTLA-230 and IMR-32 cell lines cultured 
with or without HMGB-1 (10μg/ml) by flow cytometry. 
Cells were first incubated for 30 min at 4° C with primary 
mAbs, then for 20 min with a polyclonal rabbit anti-mouse 
FITC-conjugated mAb (Dako Cytomation, Denmark). An 
isotype-matched primary mAb (Merk Millipore, Billerica, 
MA) was used as negative control. Samples were analyzed 
by Gallios flow cytometer and Kaluza software (Beckman 
Coulter, Milano, Italy). Results are expressed as MRFI 
calculated as ratio between MFI of specific mAb and MFI 
of irrelevant isotype-matched mAb.
In vitro hypoxia models
HTLA-230 and IMR-32 cell lines were incubated 
for 24, 48 and 72 h at 37° C. in a hypoxia incubator 
(Invivo2 Hypoxia Workstation, Ruskinn Technology, UK) 
which was flushed by 1% O
2
.
Image Analysis
Digital images were collected using a Nikon E-1000 
fluorescence microscope (Nikon Instruments, Tokyo, 
Japan) equipped with appropriate filter sets and the 
Genikon imaging system software (Nikon Instruments).
Oncotarget10379www.impactjournals.com/oncotarget
Statistical analysis
Statistical significance of differences between 
experimental and control groups was determined by 
ANOVA with Tukey’s multiple comparison test using 
GraphPad Prism 3.0 software (GraphPad Software, Inc.). 
Survival curves were constructed by using the Kaplan-
Meier method. Survival in different treatment groups 
was compared by using Peto’s log-rank test in StatsDirect 
0.1 statistical software (CamCode). Tumor volumes were 
compared by non parametric Mann Whitney test, one 
tailed (Confidence intervals 90%). P< 0.05 was considered 
statistically significant.
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